Free Newsletter
Hospira finishes for Genzyme
Genzyme has tapped Hospira for fill and finish of Cerezyme and Fabrazyme, helping to alleviate shortages of two key drugs. The Boston-based big biotech is still struggling to get its Allston Landing plant up to full compliance following last summer's shutdown. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: